Teva Pharmaceutical Industries Ltd. recently filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration to market a generic option to the Victoza injection.
Victoza was formulated by Novo Nordisk as an treatment for adults suffering from type 2 diabetes mellitus. Meant to work alongside diet and exercise, Victoza has been used to help regulate glycemic values.
To their knowledge, Teva is the first applicant that has filed an ANDA for this drug. If it is approved, Teva hopes to gain 180 days of generic market exclusivity.
Teva already possesses the largest number of FDA-approved generic products on the market and is waiting on the FDA registration of more than 300 drugs.
Teva intends to market generic version of Victoza
Alerts Sign-up